Impax Laboratories Inc. lost market exclusivity for its generic rendition of the antibiotic Doryx as competitor Mylan Inc. won approval for its version.
The Hayward-based drug maker (NASDAQ: IPXL) said Thursday that the Food and Drug Administration has “forfeited” Impax’s exclusivity for its 150-milligram generic Doryx.
No comments:
Post a Comment